NCT07074548Completed
Effect of Hydroxytyrosol on NLR, MLR, and SOD in Hypertensive Pregnant Women
The Effect of Hydroxytyrosol on Improving Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Superoxide Dismutase in Pregnant Women With Hypertension: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate whether hydroxytyrosol supplementation (10 mg/day for 4 weeks) is effective in improving inflammatory and oxidative stress markers in pregnant women diagnosed with hypertensive disorders of pregnancy (including preeclampsia, chronic hypertension, and gestational hypertension). The main questions it aims to answer are: 1. Does hydroxytyrosol supplementation reduce neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR)? 2. Does hydroxytyrosol supplementation lower systolic and/or diastolic blood pressure? 3. Does hydroxytyrosol supplementation increase superoxide dismutase (SOD) levels? Researchers will compare a group receiving hydroxytyrosol supplementation to a standard care control group to see if hydroxytyrosol produces superior anti-inflammatory and antioxidant effects. Participants will: * Take hydroxytyrosol 10 mg orally once daily for 4 weeks (intervention group) or receive standard antenatal care without hydroxytyrosol (control group). * Undergo laboratory testing (NLR, MLR, SOD) before and after the intervention. * Have their blood pressure monitored regularly throughout the study period.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 10 Jul 2025
- Start date
- 10 Jul 2025
- Primary completion date
- 31 Aug 2025
- Lead sponsor
- Dr Cipto Mangunkusumo General Hospital
- Diseases
- High blood pressure
- NCT number
- NCT07074548
What you commit to
- Study type: Interventional
- Participants enrolled: 42
- From 10 Jul 2025 to the primary completion date, 31 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pregnancy with infection, including chronic infections such as tuberculosis (TB), HIV, or hepatitis B
- Pregnancy with other complications (e.g., diabetes mellitus, heart disease, kidney disease, liver disease, malignancy, autoimmune disorders)
Other
- Refusal to participate in the study
Who the study is looking for
- Singleton pregnancy with a live intrauterine fetus
- Gestational age over 24 weeks. Gestational age is confirmed based on:
- Last Menstrual Period (LMP)
- First trimester ultrasound biometry
- Belongs to the Hypertensive Disorders of Pregnancy group, with the following criteria:
- Gestational hypertension and preeclampsia according to ACOG 2018 criteria
- Chronic hypertension according to ACOG 2019 criteria
- Superimposed preeclampsia according to ACOG 2018 criteria
Age in the registry: 24 years to 45 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dr. Cipto Mangunkusumo National Central Public Hospital Coordinator of this site? Confirm its status | Jakarta Pusat | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.